We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+35.52%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$376M
AUM Growth
+$68.7M
Cap. Flow
+$6.54M
Cap. Flow %
1.74%
Top 10 Hldgs %
62.6%
Holding
53
New
13
Increased
11
Reduced
14
Closed
8

Top Buys

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$10.8M
2
ARVN icon
Arvinas
ARVN
+$6.16M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$5.33M
4
CDXS icon
Codexis
CDXS
+$4.14M
5
TGTX icon
TG Therapeutics
TGTX
+$3.78M

Top Sells

Rank Stock Value
1
MOR
MorphoSys AG American Depositary Shares
MOR
+$7.82M
2
BHVN icon
Biohaven
BHVN
+$7.43M
3
TELA icon
TELA Bio
TELA
+$6M
4
GERN icon
Geron
GERN
+$4.06M
5
KALV
KalVista Pharmaceuticals
KALV
+$3.18M

Sector Composition

Rank Sector Weight
1 Healthcare 99.22%
2 Miscellaneous 0.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HROW icon
1
Harrow
HROW
$1.44B
$42.8M 11.38%
3,820,000
+25,000
+0.7% +$296K
TGTX icon
2
TG Therapeutics
TGTX
$8.53B
$37.8M 10.06%
2,215,000
+325,000
+17% +$3.78M
SLRN
3
DELISTED
ACELYRIN
SLRN
$30.9M 8.22%
4,146,138
– –
RYTM icon
4
Rhythm Pharmaceuticals
RYTM
$7.75B
$28M 7.46%
610,000
-43,000
-7% -$1.36M
OCUL icon
5
Ocular Therapeutix
OCUL
$2.38B
$27.1M 7.2%
6,070,000
-398,000
-6% -$1.18M
CPRX
6
DELISTED
Catalyst Pharmaceutical
CPRX
$21.4M 5.7%
1,257,200
+52,200
+4% +$714K
KROS icon
7
Keros Therapeutics
KROS
$223M
$14.2M 3.78%
357,500
-2,900
-0.8% -$90.9K
IDYA icon
8
IDEAYA Biosciences
IDYA
$4.03B
$11.1M 2.95%
311,500
– –
ETON icon
9
Eton Pharmaceutcials
ETON
$1.79B
$11.1M 2.95%
2,529,887
+99,617
+4% +$399K
CRNX icon
10
Crinetics Pharmaceuticals
CRNX
$9B
$10.9M 2.91%
307,500
-62,500
-17% -$1.92M
ARVN icon
11
Arvinas
ARVN
$604M
$10.9M 2.89%
+263,700
New +$6.16M
CDXS icon
12
Codexis
CDXS
$182M
$9.29M 2.47%
3,045,525
+1,926,625
+172% +$4.14M
BHVN icon
13
Biohaven
BHVN
$2.43B
$8.56M 2.28%
200,000
-239,000
-54% -$7.43M
EWTX icon
14
Edgewise Therapeutics
EWTX
$4.8B
$7.65M 2.03%
699,000
-176,405
-20% -$1.24M
IOVA icon
15
Iovance Biotherapeutics
IOVA
$3.74B
$7.29M 1.94%
897,000
+287,000
+47% +$1.5M
ARQT icon
16
Arcutis Biotherapeutics
ARQT
$3.13B
$6.33M 1.68%
+1,960,000
New +$5.33M
FDMT icon
17
4D Molecular Therapeutics
FDMT
$824M
$6.25M 1.66%
308,500
– –
MRNS
18
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$6.13M 1.63%
563,500
-20,500
-4% -$154K
PCVX icon
19
Vaxcyte
PCVX
$9.1B
$5.65M 1.5%
90,000
– –
LQDA icon
20
Liquidia Corp
LQDA
$6.26B
$5.35M 1.42%
445,000
-125,700
-22% -$905K
TARA icon
21
Protara Therapeutics
TARA
$236M
$5.05M 1.34%
2,692,594
– –
URGN icon
22
UroGen Pharma
URGN
$2.22B
$4.8M 1.28%
320,000
– –
XOMA
23
DELISTED
Xoma
XOMA
$4.63M 1.23%
250,000
-24,500
-9% -$403K
APLT
24
DELISTED
Applied Therapeutics
APLT
$3.66M 0.97%
1,092,500
+199,500
+22% +$496K
RLMD icon
25
Relmada Therapeutics
RLMD
$482M
$3.63M 0.97%
877,000
+847,000
+2,823% +$2.51M
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2023 Portfolio in Review

As of Q4 2023, Opaleye Management held 53 positions worth $376M, up 22% from $307M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opaleye Management's Q4 2023 filing shows 13 new, 11 increased, 14 reduced and 8 closed positions. Its largest new stake was Ventyx Biosciences: 1,140,000 shares worth $2.82M. The largest sale was MorphoSys AG American Depositary Shares, an estimated $7.82M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q4 2023 buy was Ventyx Biosciences: 1,140,000 shares worth $2.82M.
  • Opaleye Management added most to Codexis in Q4 2023, an estimated $4.14M increase.
  • Opaleye Management's biggest Q4 2023 reduction was MorphoSys AG American Depositary Shares, cutting an estimated $7.82M.
  • Opaleye Management fully exited TELA Bio in Q4 2023, selling an estimated $6M.
  • Opaleye Management's ten largest holdings make up 63% of its $376M portfolio in Q4 2023.
  • Opaleye Management opened 13 new positions and closed 8 in Q4 2023.
  • Opaleye Management's portfolio value rose 22% quarter-over-quarter to $376M.

Based on Opaleye Management's 13F filing for Q4 2023, filed 14 Feb 2024.